Nuformix plc (LON:NFX – Get Free Report) shot up 11.8% during trading on Tuesday . The company traded as high as GBX 0.10 ($0.00) and last traded at GBX 0.09 ($0.00). 56,631,465 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 72,646,188 shares. The stock had previously closed at GBX 0.08 ($0.00).
Nuformix Stock Down 9.7 %
The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The company has a market cap of £761,958.30, a P/E ratio of -1.63 and a beta of 1.22. The stock has a 50-day moving average of GBX 0.06 and a 200 day moving average of GBX 0.09.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) EPS for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- Business Services Stocks Investing
- Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
- Buy P&G Now, Before It Sets A New All-Time High
- Double-Digit Gains Ahead? These 2 Cybersecurity Stocks Look Ready
- Why Are These Companies Considered Blue Chips?
- Will Falling Bond Yields Send These 2 Small Caps Soaring?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
